drugset / Trial / NCT03203590
Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients
Phase 3
Unknown
590 enrolled
Sun Yat-sen University
Dongguan People's Hospital · collabMaoming Affiliated Hospital of Southern Medical University · collabShenzhen People's Hospital · collabSixth Affiliated Hospital, Sun Yat-sen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficiency and safety of Gefitinib Neoadjuvant Therapy and Oral Navelbine Carboplatin Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢA NSCLC patients with EGFR mutation.
Timeline
- Start
- 2017-09
- Primary completion
- 2026-01
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Subject | Gefitinib | Small molecule | 250 mg | Oral |
| Comparator | Vinorelbine | Small molecule | 60 mg/m2 | Oral |
Indications
No indication recorded.